Fludarabine: A phase II trial in patients with previously treated low-grade lymphoma

被引：25

作者：

Falkson, CI

机构：

[1] Department of Medical Oncology, University of Pretoria, Pretoria

[2] University of Pretoria, Pretoria, 0001

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1996年 / 19卷 / 03期

关键词：

fludarabine; low-grade lymphoma;

D O I：

10.1097/00000421-199606000-00012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of the study was to investigate the therapeutic activity of Fludarabine in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) no longer responding to standard treatment. In this Phase II study patients were treated with Fludarabine 25 mg/m(2) intravenously daily for 5 days repeated at 28-day intervals. Twenty-two patients with LC-NHL, no longer responding to standard treatment, were entered in the study. Among twenty-one evaluable patients, seven had a complete and six a partial response. The median time to treatment failure and survival time are 4.6 months and >28.0 months, respectively. The most important toxicity was hemogram suppression, which was usually manageable but occasionally severe. Fludarabine is not only an active agent with definite therapeutic value in patients with treatment-resistant LG-NHL, but effective and well tolerated in patients no longer responding to standard treatment.

引用

页码：268 / 270

页数：3

共 10 条

[1] GUIDELINES FOR CLINICAL PROTOCOLS FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - RECOMMENDATIONS OF THE NATIONAL-CANCER-INSTITUTE-SPONSORED-WORKING-GROUP [J].

CHESON, BD ;

BENNETT, JM ;

RAI, KR ;

GREVER, MR ;

KAY, NE ;

SCHIFFER, CA ;

OKEN, MM ;

KEATING, MJ ;

BOLDT, DH ;

KEMPIN, SJ ;

FOON, KA .

AMERICAN JOURNAL OF HEMATOLOGY, 1988, 29 (03) :152-163

[2] FLUDARABINE PHOSPHATE - A SYNTHETIC PURINE ANTIMETABOLITE WITH SIGNIFICANT ACTIVITY AGAINST LYMPHOID MALIGNANCIES [J].

CHUN, HG ;

LEYLANDJONES, B ;

CHESON, BD .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (01) :175-188

[3]

COHN J, 1994, P AM SOC CLIN ONCOL, V13, pA1316

[4]

HIDDEMANN W, 1993, SEMIN ONCOL, V20, P28

[5] ACTIVITY OF FLUDARABINE IN PREVIOUSLY TREATED NON-HODGKINS LOW-GRADE LYMPHOMA - RESULTS OF AN EASTERN COOPERATIVE ONCOLOGY GROUP-STUDY [J].

HOCHSTER, HS ;

KIM, K ;

GREEN, MD ;

MANN, RB ;

NEIMAN, RS ;

OKEN, MM ;

CASSILETH, PA ;

STOTT, P ;

RITCH, P ;

OCONNELL, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :28-32

[6]

MOSKOWITZ C, 1994, P ASCO, V13, P1284

[7] TOXICITY AND RESPONSE CRITERIA OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP [J].

OKEN, MM ;

CREECH, RH ;

TORMEY, DC ;

HORTON, J ;

DAVIS, TE ;

MCFADDEN, ET ;

CARBONE, PP .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (06) :649-655

[8]

PIGADITOU A, 1993, SEMIN ONCOL, V20, P24

[9]

PLUNKETT W, 1990, SEMIN ONCOL, V17, P3

[10] FLUDARABINE - AN ACTIVE AGENT IN THE TREATMENT OF PREVIOUSLY-TREATED AND UNTREATED LOW-GRADE NON-HODGKINS-LYMPHOMA [J].

ZINZANI, PL ;

LAURIA, F ;

RONDELLI, D ;

BENFENATI, D ;

RASPADORI, D ;

BOCCHIA, M ;

BENDANDI, M ;

GOZZETTI, A ;

ZAJA, F ;

FANIN, R ;

RUSSO, D ;

GALIENI, P ;

TURA, S .

ANNALS OF ONCOLOGY, 1993, 4 (07) :575-578

← 1 →